Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience
Authors:
- Ermelinda De MaioEMErmelinda De Maio
- Adriano GravinaAGAdriano Gravina
- Carmen PacilioCPCarmen Pacilio
- Gerardo AmabileGAGerardo Amabile
- Gabriella LandiGLGabriella Landi
- Francesco NuzzoFNFrancesco Nuzzo
- Emanuela RossiEREmanuela Rossi
- Giuseppe D'AIutoGDGiuseppe D'AIuto
- Immacolata CapassoICImmacolata Capasso
- Massimo RinaldoMRMassimo Rinaldo
- Brunello MorricaBMBrunello Morrica
Open Access
- 24 March 2005
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 5 (1) , 30
Abstract
Background: Few data are available on compliance and safety of adjuvant chemotherapy when indicated in elderly breast cancer patients; CMF (cyclophosphamide, methotrexate, fluorouracil) can be reasonably considered the most widely accepted standard of treatment. Methods: We retrospectively reviewed compliance and safety of adjuvant CMF in patients older than 60. The treatment was indicated if patients had no severe comorbidity, a high-risk of recurrence, and were younger than 75. Toxicity was coded by NCI-CTC. Toxicity and compliance were compared between two age subgroups (<65, ≥ 65) by Fisher exact test and exact Wilcoxon rank-sum test. Results: From March 1991 to March 2002, 180 patients were identified, 100 older than 60 and younger than 65, and 80 aged 65 or older. Febrile neutropenia was more frequent among older patients (p = 0.05). Leukopenia, neutropenia, nausea, cardiac toxicity and thrombophlebitis tended to be more frequent or severe among elderlies, while mucositis tended to be more evident among younger patients, all not significantly. Almost one half (47%) of the older patients receiving concomitant radiotherapy experienced grade 3–4 haematological toxicity. Compliance was similar in the two groups, with 6 cycles administered in 86% and 79%, day-8 chemotherapy omitted at least once in 36% and 39%, dose reduction in 27% and 38%, prolonged treatment duration (≥ 29 weeks) in 10% and 11% and need of G-CSF in 9% and 18%, among younger and older patients, respectively. Conclusion: Our data show that, in a highly selected population of patients 65 or more years old, CMF is as feasible as in patients older than 60 and younger than 65, but with a relevant burden of toxicity. We suggest that prospective trials in elderly patients testing less toxic treatment schemes are mandatory before indicating adjuvant chemotherapy to all elderly patients with significant risk of breast cancer recurrence.Keywords
This publication has 26 references indexed in Scilit:
- Disease-Free Survival Advantage of Weekly Epirubicin Plus Tamoxifen Versus Tamoxifen Alone As Adjuvant Treatment of Operable, Node-Positive, Elderly Breast Cancer Patients: 6-Year Follow-Up Results of the French Adjuvant Study Group 08 TrialJournal of Clinical Oncology, 2004
- Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast CancerJournal of Clinical Oncology, 2003
- Are Older French Patients As Willing As Older American Patients to Undertake Chemotherapy?Journal of Clinical Oncology, 2003
- Older women with breast carcinoma are less likely to receive adjuvant chemotherapyCancer, 2003
- Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinomaCancer, 2003
- Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741Journal of Clinical Oncology, 2003
- Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trialsCancer, 2002
- Patients' preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile?The Lancet Oncology, 2001
- National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000JNCI: Journal of the National Cancer Institute, 2001
- Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment TrialsNew England Journal of Medicine, 1999